Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Next Previous
Trial Profile

ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bixalomer (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma

Most Recent Events

  • 08 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
  • 17 Mar 2015 According to media release, Astellas Pharma has submitted a supplemental New Drug Application (sNDA) to the Ministry of Health, Labour and Welfare in Japan, for bixalomer [Kiklin] for treatment of hyperphosphatemia in patients with chronic kidney disease who are not on dialysis. Data from this and another phase III trial (CTP 700245024) were used in the sNDA application.
  • 15 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top